Amgen at ACC.14

Amgen will present the results from five Phase 3 studies of evolocumab (AMG 145) at the American College of Cardiology’s 63rd Annual Scientific Session (ACC.14), taking place in Washington, D.C., March 29-31, 2014.

Follow Amgen on Twitter at http://twitter.com/amgen to receive news updates during ACC.14.

Mar. 30, 2014	Data From Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On Statins
Mar. 29, 2014	New Detailed Data from Three Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medicine Evolocumab Significantly Reduced LDL Cholesterol By 55-66 Percent Compared To Placebo In Patients With High Cholesterol
Mar. 26, 2014	Amgen To Webcast Investor Meeting At Upcoming American College of Cardiology's 63rd Annual Scientific Session
Mar. 24, 2014	Phase 3 Pivotal Data On Amgen’s Novel Investigational Cholesterol-Lowering Medicine To Be Featured At The American College Of Cardiology’s 63rd Annual Scientific Session

Amgen at ACC.14

Share This Story